Humoral alloimmunity

SUNDAY 24 SEPTEMBER 2017 | 09:00-12.50

CHAIRS:  Fritz Diekmann, Berlin, Germany
               Ondrej Viklicky, Prague, Czech Republic

09:00-10:40            SESSION 1 

09:00                      Basics of the HLA system
                              Caner Süsal, Heidelberg, Germany

09:20                      External validity and variability of solid phase results
                              Markus Wahrmann, Vienna, Austria

09:40                      HLA single epitope matching become real?
                              Frans Claas, Leiden, The Netherlands

10:00                      Preformed HLA DSAs and outcomes
                              Christophe Legendre, Paris, France

10:20                      De novo HLA-DSAs and hard outcomes. How to determine risk (class, number, complement activation?)
                              Johan W. De Fijter, Leiden, The Netherlands

10:40 - 11:00           Break     

11:00-12:50            SESSION 2 

11:00                      Alloimmunity trough non-HLA, the human knock out experiment
                             Rainer Oberbauer, Vienna, Austria

11:20                      Complement blockade and outcomes – novel approaches beyond eculizumab
                              Georg Böhmig, Vienna, Austria

11:40                      Treatment of ABMR features in management biopsies
                              Ondrej Viklicky, Praha, Czech Repuplic

12:00                      Underlying mechanisms of spontaneous operational tolerance
                              Annick Massart, Brussels, Belgium



OBJECTIVES | To provide an overview and offer specific solutions for the ‘complicated’/sensitized patient. Solutions range from individualization through omics technologies to bioinformatics approaches.

TARGET AUDIENCE | Transplant surgeons and physicians, nephrologist, immunologists at all stages of training and expertise.


EKITA is the kidney section of ESOT and deals with all aspects of renal transplantation. As a European platform, EKITA supports research, education and clinical work in this area. Furthermore, EKITA is highly ambitious in preparing policies and creating transnational interactions to advance renal allografting in all European member states.

GOALS |The main goal of EKITA is to improve quality of life of people with ESRD by advancing all aspects of kidney transplantation.

AIM |The ultimate aim of EKITA is the optimization of renal transplantation trough activities in research, education, clinical collaboration and health policy.